Please assess the completion status of the following clinical trial:

Trial Title: Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males, and females not of child-bearing potential (surgically sterile or at least one year postmenopausal), of at least 50 years of age~* Probable Alzheimer's disease according to the NINCDS-ADRDA (National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association) and DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) criteria~* MMSE (Mini-Mental State Examination) score of \> 10 and \< 26~* Patients initiating therapy for the first time with a cholinesterase inhibitor (patients prescribed both rivastigmine and memantine are allowed)~* Patients who failed to benefit from previous cholinesterase inhibitor treatment~Exclusion Criteria:~* Patients not treated according to the product monograph for rivastigmine capsules~* patients involved in a clinical trial~* Current diagnosis of an active skin lesion/disorder that would prevent accurate assessment of the adhesion and potential skin irritation of the patch (e.g., atopic dermatitis, wounded or scratched skin in the area of the patch application)~Other protocol-defined exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivastigmine 5 and 10 cm^2 patch (Type: EXPERIMENTAL): For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm\^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm\^2 patch, with adjustments as necessary for safety and tolerability.

Based on this trial design, predict the completion outcome and termination type (if applicable).